metabolic product News
-
Agilent Technologies Presents Thought Leader Award to Human Microbiome Expert Jeffrey Gordon
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Jeffrey Gordon has received an Agilent Thought Leader Award in support of his pioneering research into the mutually beneficial relationship between the human body and the tens of trillions of microbes that inhabit the gastrointestinal tract. Dr. Gordon directs the Center for Genome Sciences and Systems Biology at Washington University ...
-
Full-Scale Mitochondrial Bioenergetics Services at Creative Biogene
New York, United States—May 18, 2022—As one of leading bio-companies engaged in mitochondrial research, Creative Biogene, together with its large team of experts, create a powerful mitochondrial research service platform. To satisfy the research needs of global customers on mitochondrial bioenergies, Creative Biogene provides partners with comprehensive range of mitochondrial bioenergetics ...
-
Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health
Creative Enzymes, a trailblazing leader in the field of enzyme research and manufacturing, is excited to announce its latest innovation: Diamine Oxidase (Food Grade). This product is poised to revolutionize the food industry by significantly bolstering food safety protocols and promoting optimal digestive health. Histamine intolerance, stemming from reduced levels of Diamine Oxidase (DAO), is a ...
-
Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear’s HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced the publication of in vitro pharmacology data in the journal Molecular Genetics and Metabolism, demonstrating that the oral small molecule HST5040 may be effective in treating Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA). The company has initiated the HERO (HElp ...
-
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval TSC was safe and well-tolerated by all subjects with no serious adverse events reported Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) ...
By CervoMed
-
Alfa Chemistry Now Offers Pharmaceutical and Drug Standards for Drug Discovery
Uniquely positioned to be a dedicated player in the analytical testing industry, Alfa Chemistry supplies a full range of analytical reagents. Today it announces to add pharmaceutical and drug standards to its already rich offering of chromatography standards. After this move, researchers can now easily have access to certified reference materials, environmental standards, food & beverage ...
-
MedBiome licenses the RapidAIM technology from the University of Ottawa
MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the ...
-
Creative BioMart Provides a Wide Range of Centromere Proteins for Research Use
Creative BioMart, a world leading biotech company specialized in providing quality protein products and services to customers all over the world now provides a wide selection of centromere proteins for cancer research. Centromeres are specialized DNA sequences in chromosomes, which hold two daughter chromatids together. Centromeres represent a contractile region of the chromosome in which two ...
-
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” ...
-
Creative Proteomics Announces the Launch of Its New Metabolomics Division
Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and ...
-
Creative Proteomics Announces the Launch of Its New Metabolomics Division
Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and ...
-
Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. Creative Proteomics Metabolomics announced the launch of the Gut Microbiota Metabolomics Service, aiming to detect the dynamic changes in enterobacterial metabolites and clearly ...
-
Traffic pollution associated with risk of developing type 2 diabetes
Long-term exposure to traffic-related air particle pollution is linked with type 2 diabetes, a new study in Germany has found. Furthermore, the study found that people living close to busy roads were at greater risk of developing the disease than those living further away. Air pollution has been linked to a number of health problems, including heart, circulatory and lung diseases. It has also ...
-
Creative Proteomics Lipidomics Platform Boosts Short Chain Fatty Acids Research
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, and biotechnological and pharmaceutical companies. The Lipidomics platform now employs gas chromatography-mass spectrometry (GC-MS) methods to enable fast and accurate qualitative and quantitative analysis of a ...
-
Creative Proteomics's Targeted Metabolomic Platform Supports Ketone Body Detection
Creative Proteomics is an experienced outsourcing service provider offering professional and high-quality multi-omics services to academic research institutions and pharmaceutical industry. Creative Proteomics offers targeted metabolomics services for the enrichment and accurate quantitative profiling of a specific metabolite in blood, urine or other body fluids and tissues under specific ...
-
Berkshire Biomedical Appoints John E. Timberlake as CEO
Berkshire Biomedical, LLC (“Berkshire” or “the Company”), a privately-held digital health company developing a revolutionary virtual care prescription drug delivery and management system only for the Intended User, today announced the appointment of John E. Timberlake as President and Chief Executive Officer. In addition, Mr. Timberlake will serve as a member of the ...
-
Eagle Pharmaceuticals Provides Business Update and Guidance for 2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from ...
-
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you